Chronic graft versus host disease in the intestine is a serious complication that can develop after receiving donor stem cells through an allogeneic transplant, where the donated immune cells mistakenly attack the recipient’s digestive system.

What Is Chronic Graft Versus Host Disease in the Intestine?

When someone undergoes an allogeneic stem cell transplant (a transplant using cells from another person), their body receives healthy stem cells from a donor to replace damaged or diseased cells. However, these donor cells can sometimes view the recipient’s body as a threat and launch an attack against it. This is called graft versus host disease, or GVHD. The term “graft” refers to the donated cells, while “host” refers to the person receiving them.^[1]

Chronic GVHD affecting the intestine develops differently than the acute form of this condition. While acute GVHD typically appears within the first 100 days after transplant, chronic GVHD usually develops later, often between five to six months after the procedure, though it can appear at any time.^[17] Many people who develop chronic GVHD previously experienced acute GVHD, but this is not always the case. What makes chronic GVHD particularly challenging is that it can affect more organs and tissues than acute GVHD, and patients may no longer be having frequent visits with their transplant team when symptoms first appear.^[17]

The gastrointestinal tract is one of the most commonly affected areas in GVHD. Roughly 70% of patients with acute GVHD and 33% of patients with chronic GVHD experience involvement of the digestive system.^[4] The condition is particularly concerning because intestinal GVHD can be severe and significantly impact a patient’s overall health and quality of life. When the digestive system is attacked, it can interfere with a person’s ability to eat, absorb nutrients, and maintain their strength during recovery from transplant.^[6]

How Common Is This Condition?

Graft versus host disease is a frequent complication following allogeneic hematopoietic stem cell transplantation. The digestive system, particularly the intestines, is one of the primary targets of this immune reaction. Because intestinal involvement is so common in GVHD patients, medical teams closely monitor transplant recipients for any signs of gastrointestinal problems.^[4]

Certain patients face a higher risk of developing chronic GVHD in the intestine. Those who previously had acute GVHD are more likely to develop the chronic form. Older patients, those who received stem cells from an unrelated donor or from a donor who was not a perfect genetic match, and those who were transplanted with stem cells collected from the bloodstream rather than bone marrow or cord blood all face increased risk.^[17]

Additionally, male patients who receive cells from female donors, especially female donors who have previously been pregnant, have a higher likelihood of developing chronic GVHD. This is because previous pregnancies can sensitize a woman’s immune system to certain proteins, which can then affect the transplant recipient.^[17]

What Causes Chronic GVHD in the Intestine?

The root cause of chronic GVHD in the intestine stems from an immune system mismatch. After an allogeneic stem cell transplant, the donor’s immune cells are supposed to rebuild the recipient’s immune system. However, these donor cells may recognize the recipient’s tissues as foreign because of differences in proteins called human leukocyte antigens, or HLA. These proteins help the immune system distinguish between the body’s own cells and foreign invaders.^[2]

When the donor immune cells identify the recipient’s tissues as threats, they mount an attack. In the case of intestinal GVHD, immune cells called T lymphocytes from the donor recognize the recipient’s intestinal tissues as foreign and begin attacking them. These T cells are critical for the development of GVHD, and removing them from donor bone marrow grafts can effectively prevent the disease, though this approach has other complications.^[6]

The process of developing chronic GVHD is complex. It may result from damage to the thymus, an organ that helps train immune cells to recognize what belongs in the body and what doesn’t. When the thymus is damaged by the conditioning regimens used before transplant, by acute GVHD itself, or by age-related changes, self-reactive T cells may escape this training process. These poorly trained immune cells can then attack the body’s own tissues, leading to chronic GVHD with features similar to autoimmune diseases.^[9]

Risk Factors for Developing Intestinal Chronic GVHD

Several factors can increase the likelihood of developing chronic GVHD affecting the intestines. Understanding these risk factors helps patients and healthcare teams stay vigilant for early signs of the condition.

The type of conditioning regimen (the chemotherapy and sometimes radiation given before transplant) influences GVHD risk. Different conditioning treatments can affect how well-matched the donor and patient cells interact with each other.^[4] More intensive conditioning regimens may increase the risk of GVHD by causing more tissue damage before the transplant.

The degree of genetic matching between donor and recipient plays a significant role. Transplants using cells from donors who are not perfectly matched or who are unrelated to the recipient carry higher GVHD risk. This is because there are more genetic differences for the donor immune cells to recognize as foreign.^[1]

Gender combinations between donor and recipient matter as well. When a male patient receives stem cells from a female donor, especially one who has been pregnant before, the risk of chronic GVHD increases. Pregnancy exposes a woman’s immune system to her child’s paternal antigens, potentially making her immune cells more reactive when transplanted into another person.^[17]

Patients who develop peripheral blood stem cell transplants rather than bone marrow transplants have been found to have a higher incidence of chronic GVHD. Peripheral blood contains more T cells than bone marrow, which may contribute to this increased risk.^[1]

Age is another factor, with older patients facing greater risk of developing chronic GVHD. This may be related to age-related changes in the thymus and immune system function.^[17] Additionally, patients who experienced acute GVHD earlier in their post-transplant course have a higher likelihood of subsequently developing chronic GVHD.^[17]

Symptoms of Chronic GVHD in the Intestine

Chronic GVHD affecting the intestines and digestive system can cause a range of uncomfortable and sometimes debilitating symptoms. The digestive system includes the mouth, esophagus (food pipe), stomach, intestines, and rectum, meaning symptoms can appear anywhere along this pathway.^[8]

In the mouth, patients may experience dryness, painful sores, and sensitivity to spicy or acidic foods. Some people develop painless white lines on their tongue or inner cheeks. Difficulty opening the mouth fully can also occur, which can interfere with eating and oral hygiene.^[5][7]

When chronic GVHD affects the esophagus and lower digestive tract, patients commonly experience nausea and vomiting. Heartburn may develop as the lining of the esophagus becomes irritated. Loss of appetite is frequent, making it difficult to maintain adequate nutrition.^[4]

Diarrhea is one of the most common and troublesome symptoms of intestinal chronic GVHD. The diarrhea can range from mild to severe and may be accompanied by abdominal cramping or pain. Weight loss often follows, both from the diarrhea itself and from reduced food intake due to other digestive symptoms.^[4][7]

The severity of chronic GVHD in the digestive system is assessed based on several factors: how difficult it is to eat, whether there is narrowing of the esophagus that makes swallowing hard, whether weight loss is occurring, and how much the symptoms impact daily activities. These assessments help guide treatment decisions.^[4]

Some patients describe living with intestinal GVHD as feeling like their guts are on fire, with alternating pain and nausea that can become overwhelming. The unpredictable nature of symptoms can make it difficult to plan daily activities or maintain normal routines.^[13] The cumulative effect of these digestive symptoms can lead to malnutrition, dehydration, and a significant decrease in quality of life.^[6]

Prevention Strategies

Preventing chronic GVHD in the intestine begins with careful management from the time of transplant. The standard approach to GVHD prevention involves giving patients immunosuppressive medications that calm the immune system and reduce the likelihood of donor cells attacking the recipient’s tissues.^[11]

The most common preventive regimen combines a medication called cyclosporine with short-course methotrexate. Cyclosporine levels must be carefully monitored and kept above certain thresholds to be effective. Sometimes another drug called tacrolimus is used instead of cyclosporine, particularly when the donor is unrelated to the recipient, as it may provide better GVHD control in those situations.^[11]

Other medications have been studied for GVHD prevention, including mycophenolate mofetil, sirolimus, and various combinations of immunosuppressive agents. The choice of preventive medications depends on many factors, including the type of transplant, donor-recipient matching, and individual patient characteristics.^[11]

Some transplant centers use antithymocyte globulin (ATG) before the transplant, which can significantly reduce the risk of severe acute and chronic GVHD. However, this approach doesn’t necessarily improve overall survival because it may increase the risk of infections.^[11]

Removing T cells from the donor graft before transplantation is another prevention strategy that has been explored. While this effectively prevents GVHD, it can lead to other complications and hasn’t been shown to improve overall outcomes compared to standard treatments in patients receiving well-matched grafts.^[11]

After transplant, regular self-monitoring becomes crucial for early detection of chronic GVHD. Patients should examine their bodies weekly, carefully inspecting their mouth, skin, and monitoring for any digestive symptoms. Reporting any unusual changes to the healthcare team immediately allows for prompt intervention, which can prevent symptoms from becoming severe.^[17]

How Chronic Intestinal GVHD Affects the Body

At a cellular and tissue level, chronic GVHD causes significant changes to normal intestinal function. The condition damages the lining of the digestive tract, disrupting its ability to absorb nutrients, water, and essential vitamins and minerals. This damage occurs when donor T cells recognize the recipient’s intestinal cells as foreign and mount an immune attack against them.^[6]

The intestinal lining normally acts as both a barrier and an absorption surface. It prevents harmful bacteria and toxins from entering the bloodstream while allowing nutrients to pass through. When GVHD damages this lining, it becomes inflamed and can develop ulcers or erosions. The barrier function breaks down, potentially allowing bacteria and bacterial products like endotoxins to leak from the intestinal space into the bloodstream. This can trigger further inflammation and immune activation throughout the body.^[9]

The damage to the intestinal lining also severely impairs nutrient absorption. Even when patients try to eat, their bodies cannot properly extract calories, proteins, fats, vitamins, and minerals from food. This leads to malnutrition despite food intake. The decreased absorption of nutrients and hydration, combined with ongoing diarrhea, creates a cycle of worsening nutritional status and physical weakness.^[6]

Chronic GVHD can cause tissue thickening and scarring in the digestive tract, a process called fibrosis. In severe cases, this scarring can narrow parts of the esophagus or intestines, making it physically difficult for food to pass through. This narrowing, called stricture, may require additional procedures to stretch or open the affected areas.^[5]

The mouth is often affected by chronic GVHD, with damage to the salivary glands reducing saliva production. Saliva is essential for beginning the digestive process, protecting tooth enamel, and preventing infections in the mouth. Without adequate saliva, patients experience dry mouth, increased risk of dental cavities and gum disease, and difficulty swallowing.^[17]

When the liver is also affected by chronic GVHD (which occurs in roughly a third of chronic GVHD patients), it can interfere with the production of bile and other substances needed for digestion. The liver may become inflamed and scarred, potentially progressing to cirrhosis in severe cases. Liver involvement can cause yellowing of the skin and eyes (jaundice), swelling in the legs and abdomen, and increased bleeding tendencies.^[4]

The chronic inflammation and tissue damage caused by intestinal GVHD places enormous stress on the body. Patients must fight not only the GVHD itself but also the consequences of malnutrition, dehydration, and the disruption of normal digestive processes. This is why chronic intestinal GVHD can be particularly debilitating and why comprehensive, supportive care is so important for managing the condition.^[6]